HER3 Rationale Text Module

CME

Expanding Our Understanding of HER3 Expression, Implications, and Rationale for HER3-Targeted Therapy in Solid Tumors

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: October 20, 2023

Expiration: October 19, 2024

Misako Nagasaka
Misako Nagasaka, MD, PhD

Activity

Progress
1
Course Completed

References

  1. Lyu H, Han A, Polsdofer E, et al. Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharm Sin B. 2018;8:503-510.
  2. Uliano J, Corvaja C, Curigliano G, et al. Targeting HER3 for cancer treatment: a new horizon for an old target. ESMO Open. 2023;8:100790.
  3. Mishra R, Patel H, Alanazi S, et al. HER3 signaling and targeted therapy in cancer. Oncol Rev. 2018;12:355.
  4. Laskin J, Liu SV, Tolba K, et al. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. Ann Oncol. 2020;31:1693-1703.
  5. Werr L, Plenker D, Dammert MA, et al. CD74-NRG1 fusions are oncogenic in vivo and induce therapeutically tractable ERBB2:ERBB3 heterodimerization. Mol Cancer Ther. 2022;21:821-830.
  6. Shin S, Cho SI, Choi S, et al. Exploring expression levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 cancer types using an artificial intelligence-powered immunohistochemistry analyzer. Presented at: 2023 American Society of Clinical Oncology Annual Meeting; June 2-6, 2023. Abstract 3135.
  7. Li Q, Zhang R, Yan H, et al. Prognostic significance of HER3 in patients with malignant solid tumors. Oncotarget. 2017;8:67140-67151.
  8. Jänne PA, Yu HA, Johnson ML, et al. Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC. Presented at: 2019 American Society of Clinical Oncology Annual Meeting; May 31 - June 4, 2019. Abstract 9010.
  9. Ocana A, Vera-Badillo F, Seruga B, et al. HER3 overexpression and survival in solid tumors: a meta-analysis [published correction appears in J Natl Cancer Inst. 2013;105:944]. J Natl Cancer Inst. 2013;105:266-273.
  10. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437-441.
  11. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-1043.
  12. Bosch-Vilaró A, Jacobs B, Pomella V, et al. Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells. Oncotarget. 2017;8:4277-4288.
  13. Wang S, Huang X, Lee CK, Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene. 2010;29:4225-4236.
  14. Xia W, Petricoin EF 3rd, Zhao S, et al. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. Breast Cancer Res. 2013;15:R85.
  15. Yonesaka K, Tanizaki J, Maenishi O, et al. HER3 augmentation via blockade of EGFR/AKT signaling enhances anticancer activity of HER3-targeting patritumab deruxtecan in EGFR-mutated non-small cell lung cancer. Clin Cancer Res. 2022;28:390-403.